Travere Therapeutics raises 2018 equity plan share reserve to 25,384,114 shares

• Travere Therapeutics adopted amendments to its 2018 Equity Incentive Plan, with the latest board action dated March 29, 2026 and stockholder approval dated May 19, 2026.
• The plan’s share reserve totals 25,384,114 shares of common stock, before any additional shares that return to the reserve from forfeitures, expirations, cancellations, or cash settlements.
• Incentive stock options are capped at 8,000,000 shares.
• Non-employee director pay under the plan is capped at $750,000 in total value per annual meeting-to-annual meeting period, or $1.25 million for a newly appointed or elected director during that period.
• Options or SARs typically expire 10 years from grant, with a post-termination exercise window of 3 months, extended to 12 months for disability or 18 months for death unless an award agreement sets different terms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001438533-26-000046), on May 21, 2026, and is solely responsible for the information contained therein.